Denali Therapeutics Inc. 8-K

What Happened

• On May 7, 2026, Denali Therapeutics Inc. announced its financial results for the quarter ended March 31, 2026 via a press release. The full text of the press release is attached to the Form 8-K as Exhibit 99.1 and is incorporated by reference into the filing.

Key Details

• Filing date: May 7, 2026.
• Period covered: quarter ended March 31, 2026.
• Press release attached as Exhibit 99.1 to the Form 8-K (investors should open Exhibit 99.1 for the actual financial figures).
• The information in the filing and Exhibit 99.1 is furnished (not “filed”) and therefore is not subject to Section 18 liability and is not incorporated by reference into other filings under the Securities Act or Exchange Act, except where expressly stated.

Why It Matters

• This 8-K provides Denali’s latest quarterly results and commentary, which are material for investors tracking earnings, revenue trends, cash position, or program progress.
• Because the press release is furnished rather than filed, it is available for review but carries the different legal treatment noted above; investors should review Exhibit 99.1 for the specific financials and any management commentary before making decisions.